'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer

Ann Oncol. 2013 Jul;24(7):1715-1717. doi: 10.1093/annonc/mdt172. Epub 2013 May 12.

Authors

D Santini¹, B Vincenzi², F Pantano³, G Schiavon⁴, G Tonini²

Affiliations

¹ Medical Oncology Department, University Campus Bio-Medico, Rome, Italy. Electronic address: d.santini@unicampus.it.
² Medical Oncology Department, University Campus Bio-Medico, Rome, Italy.
³ Medical Oncology Department, University Campus Bio-Medico, Rome, Italy; INSERM, Research Unit U1033, University of Lyon-1, Faculty of Medicine Laennec, Lyon, France.
⁴ Breast Unit, The Royal Marsden NHS Foundation Trust, London, UK.

PMID: 23670095
DOI: 10.1093/annonc/mdt172

No abstract available

Publication types

Editorial
Comment

MeSH terms

Adenocarcinoma / genetics*
Esophageal Neoplasms / genetics*
Esophagogastric Junction / pathology*
Female
Gene Amplification*
Humans
Male
Receptor, ErbB-2 / genetics*
Stomach Neoplasms / genetics*

Substances

ERBB2 protein, human
Receptor, ErbB-2